Reaffirming revenue guidance, especially when it aligns closely with analyst estimates, typically instills confidence in investors about the company's financial health and operational stability. This announcement is likely to have a positive impact on Catalyst Pharmaceuticals' stock price in the short term as it reassures investors of the company's growth trajectory and financial planning accuracy.